No Data
No Data
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Is Definitely on the Radar of Institutional Investors Who Own 47% of the Company
H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating
H.C. Wainwright analyst Mitchell Kapoor maintains $CytomX(CTMX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 33.1% and a total average return of -15.8% over the
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 28%
To the annoyance of some shareholders, CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares are down a considerable 28% in the last month, which continues a horrid run for the company. The drop over the
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean
Express News | CytomX Therapeutics Promotes Chris Ogden To Chief Financial Officer; Effective June 15, 2024
Express News | CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
No Data